Viking Therapeutics Stock Plummets 40% Despite Positive Clinical Trial Results

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-08-19 15:43:02

BTCCSquare news:

Viking Therapeutics (VKTX) shares tumbled 40% on Tuesday despite reporting positive Phase 2 data for its metabolic disorder drug VK2735. The dual GLP-1/GIP receptor agonist showed significant weight loss results, with 80% of trial participants achieving over 10% reduction—far exceeding placebo outcomes.

CEO Brian Lian emphasized the drug's potential for long-term weight maintenance, citing progressive efficacy curves. However, investor concerns surfaced around the 20% discontinuation rate due to adverse events, nearly double the placebo group's figure.

By:

Log in to Reply

Pi Coin Consolidates at $0.36 Amid 142% Volume Surge, $0.50 Breakout Potential on Mainnet Migration Catalyst

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.